Stephen Ray Mitchell - Net Worth and Insider Trading
Stephen Ray Mitchell Net Worth
The estimated net worth of Stephen Ray Mitchell is at least $207,239 dollars as of 2024-12-13. Stephen Ray Mitchell is the Director of Vanda Pharmaceuticals Inc and owns about 44,857 shares of Vanda Pharmaceuticals Inc (VNDA) stock worth over $207,239. Details can be seen in Stephen Ray Mitchell's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Stephen Ray Mitchell has not made any transactions after 2024-11-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Stephen Ray Mitchell
Stephen Ray Mitchell Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Stephen Ray Mitchell owns 1 companies in total, including Vanda Pharmaceuticals Inc (VNDA) .
Click here to see the complete history of Stephen Ray Mitchell’s form 4 insider trades.
Insider Ownership Summary of Stephen Ray Mitchell
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
VNDA | Vanda Pharmaceuticals Inc | 2024-11-14 | director |
Stephen Ray Mitchell Latest Holdings Summary
Stephen Ray Mitchell currently owns a total of 1 stock. Stephen Ray Mitchell owns 44,857 shares of Vanda Pharmaceuticals Inc (VNDA) as of November 14, 2024, with a value of $207,239.
Latest Holdings of Stephen Ray Mitchell
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
VNDA | Vanda Pharmaceuticals Inc | 2024-11-14 | 44,857 | 4.62 | 207,239 |
Holding Weightings of Stephen Ray Mitchell
Stephen Ray Mitchell Form 4 Trading Tracker
According to the SEC Form 4 filings, Stephen Ray Mitchell has made a total of 5 transactions in Vanda Pharmaceuticals Inc (VNDA) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Vanda Pharmaceuticals Inc is the sale of 5,000 shares on November 14, 2024, which brought Stephen Ray Mitchell around $25,850.
Insider Trading History of Stephen Ray Mitchell
- 1
Stephen Ray Mitchell Trading Performance
Stephen Ray Mitchell Ownership Network
Ownership Network List of Stephen Ray Mitchell
Ownership Network Relation of Stephen Ray Mitchell
Stephen Ray Mitchell Owned Company Details
What does Vanda Pharmaceuticals Inc do?
Who are the key executives at Vanda Pharmaceuticals Inc?
Stephen Ray Mitchell is the director of Vanda Pharmaceuticals Inc. Other key executives at Vanda Pharmaceuticals Inc include VP & Acting CFO & Treasurer Kevin Patrick Moran , director & Chief Executive Officer Mihael Hristos Polymeropoulos , and SVP & General Counsel Timothy Williams .
Vanda Pharmaceuticals Inc (VNDA) Insider Trades Summary
Over the past 18 months, Stephen Ray Mitchell made 2 insider transaction in Vanda Pharmaceuticals Inc (VNDA) with a net sale of 11,500. Other recent insider transactions involving Vanda Pharmaceuticals Inc (VNDA) include a net sale of 35,163 shares made by Kevin Patrick Moran , a net sale of 20,451 shares made by Joakim Wijkstrom , and a net sale of 55,172 shares made by Mihael Hristos Polymeropoulos .
In summary, during the past 3 months, insiders sold 5,000 shares of Vanda Pharmaceuticals Inc (VNDA) in total and bought 0 shares, with a net sale of 5,000 shares. During the past 18 months, 156,785 shares of Vanda Pharmaceuticals Inc (VNDA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 156,785 shares.
Vanda Pharmaceuticals Inc (VNDA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Vanda Pharmaceuticals Inc Insider Transactions
Stephen Ray Mitchell Mailing Address
Above is the net worth, insider trading, and ownership report for Stephen Ray Mitchell. You might contact Stephen Ray Mitchell via mailing address: C/o Vanda Pharmaceuticals Inc., 2200 Pennsylvania Ave., Suite 300e, Washington Dc 20037.